Volume 23 - Special issue                   mjms 2021, 23 - Special issue: 30-39 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bahrulolum H, Nooraei S, Bokaie S, Houshmandi K, Raei M, Entezari M. Candidate inhibitors against the main protease of SARS-CoV-2. mjms. 2021; 23 :30-39
URL: http://mjms.modares.ac.ir/article-30-46220-en.html
1- Ph.D. Candidate, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran
2- Full Professor, Department of Food Hygiene and Quality Control, Division of Epidemiology & Zoonoses, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
3- Ph.D. Candidate, Department of Food Hygiene and Quality Control, Division of Epidemiology & Zoonoses, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
4- Assistant Professor, Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
5- Associate Professor, Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran , medicine.med2000@yahoo.com
Abstract:   (894 Views)
Covid-19 is a highly infectious viral disease caused by SARS-CoV-2, which has spread worldwide since its emersion in December 2019, causing an unprecedented pandemic. Currently, it has no targeted vaccines or treatments, and effective treatment options are very limited. It is important to identify drugs that effectively inhibit a specific target of the SARS coronavirus. This is the third deadly outbreak of coronaviruses in human society which has put pressure on the global health care system and affected the global economy a well. However, the treatment options of Covid-19 are still very limited. The development of drugs that target and inhibit essential proteins in the viral life cycle is a practical approach to overcoming this hard situation. The main protease, a cysteine protease, is an attractive target for antiviral drugs against SARS-CoV-2 and other coronavirus infections due to its essential role in viral replication and transcription. To quickly detect effective compounds for clinical use, programs such as molecular docking drug design and virtual screening of pre-designed drugs to identify new compounds and drugs that target the main protease of the COVID-19 are performed. Combining these structural studies, virtual screening, and experimental screen, several therapeutic candidates such as repurposed drugs and ab initio designed drugs have been proposed. In this review study, suggestions for inhibitors and possible potentially effective drugs against the main protease of SARS-CoV-2 were discussed. This study paves the way for advanced experimental research to evaluate the pharmacological potential of these compounds for the treatment of Covid-19.
Full-Text [PDF 1537 kb]   (206 Downloads)    
Article Type: Analytic Review | Subject: Virology
Received: 2020/09/21 | Accepted: 2021/02/8

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.